Next Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Next Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$72K	Buy	609 +13	+2%	+$1.63K	﹤0.01%	1315
2021 Q3	$80K	Sell	596 -92	-13%	-$13.9K	0.01%	1215
2021 Q2	$111K	Sell	688 -398	-37%	-$31K	0.01%	1073
2021 Q1	$87K	Buy	1,086 +963	+783%	+$64.6K	0.01%	1078
2020 Q4	$6K	Buy	123 +23	+23%	+$835	﹤0.01%	1936
2020 Q3	$2K	Buy	+100	New	+$2.08K	﹤0.01%	2036
2020 Q2	–	Sell	-100	Closed	-$1K	–	1454
2020 Q1	$1K	Hold	100	–	–	﹤0.01%	2033
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	2287
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	2239
2019 Q2	$2K	Buy	+100	New	+$1.57K	﹤0.01%	2132
2019 Q1	–	Sell	-59	Closed	-$1K	–	1968
2018 Q4	$1K	Buy	+59	New	+$1.1K	﹤0.01%	1865

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Next Financial Group's NTLA Position: Q4 2021 in Review

Next Financial Group increased its Intellia Therapeutics (NTLA) stake by 2.2% in Q4 2021, buying an estimated $1.63K and bringing the position to 609 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Next Financial Group first reported a position in NTLA in Q4 2018 and has held it in 11 quarters since. The position peaked at $111K in Q2 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

Next Financial Group held 609 shares of Intellia Therapeutics worth $72K as of Q4 2021.
Next Financial Group bought 13 Intellia Therapeutics shares in Q4 2021, an estimated $1.63K.
Intellia Therapeutics made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #1315 holding.
Next Financial Group first reported a position in Intellia Therapeutics in Q4 2018 and has held it in 11 quarters since.
Next Financial Group's Intellia Therapeutics position peaked at $111K in Q2 2021.
371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.